[1] RON DA, VERA R, Labandeira CM, et al.Maintenance treatment in metastatic colorectal cancer: in search of the best strategy[J]. Clinical and Translational Oncology, 2020, 22(5): 1205-1215. [2] AL-HILLAN A, AL-BANAA K, MOHAMED M, et al.A case of late recurrence of colon cancer after curative treatment[J]. Cureus, 2020, 12(5): e8083. [3] WU DH, WANG DS.Clinical etiology and risk factors of acute kidney injury[J]. Chinese Journal of Modern Medicine(中国现代医学杂志), 2015, 25(5): 61-65. [4] FENG Z, CHEN XM.Prevention and treatment of acute kidney injury in China[J]. West China Medicine(华西医学), 2018, 33(7): 777-781. [5] JIANG N, SUN L.Interpretation of expert consensus on ADQI acute kidney disease and Renal Recovery in 2017[J]. Chinese Journal of Nephropathy Research(中华肾病研究电子杂志), 2017, 6(6): 278-281. [6] LI GH, YANG J.Clinical Work Manual of Oncology Pharmacists(肿瘤专科药师临床工作手册)[M]. Beijing: People's Medical Publishing House, 2018: 80-82. [7] National Health and Family Planning Commission expert Committee on Rational Drug Use. Guidelines on rationa Drug Use for Gastrointestinal Malignancies[J]. Exploration of Rational Drug Use in China(中国合理用药探索), 2017, 14(9): 5-54. [8] BONVENTRE JV YL.Cellular pathophysiology of ischemic acute kidney injury[J]. J Clin Invest, 2011, 121: 4210-4221. [9] ZENG WQ, SHEN J, GONG Q.The path of armaceutical care for tumor therapy(肿瘤治疗药学监护路径)[M]. Shanghai: World Book Publishing Company, 2019: 71-73. [10] FANG WT, GU YH.Drug selection for the treatment of colorectal cancer with complications[J]. Chinese Electronic Journal of Colorectal Diseases(中华结直肠疾病电子杂志), 2018, 7(5): 420-429. [11] PINSKY PF, SCHOEN RE.Contribution of surveillance colonoscopy to colorectal cancer prevention[J]. Clinical Gastroenterology and Hepatology, 2020, 18(13): 2937-2944. [12] LI QY, CHEN J, WANG G.Effects of "hidden kidney lesion" on the safety and efficacy of capecitabine in the treatment of advanced colorectal cancer[J]. Chinese Modern Applied Pharmacy(中国现代应用药学), 2014, 31(6): 748-751. [13] ZHU JL, ZHOU YN, YUAN WZ, et al.Comparison of adverse reactions after neoadjuvant chemotherapy with oxaliplatin combined with tegor and oxaliplatin combined with capecitabine for gastric cancer[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(1): 17-22. [14] ZHAI SY, CUI R, et al.Analysis of 4120 adverse reactions of anti-umor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(5): 291-294. [15] ZHANG XM, CAI J.Drug analysis of renal injury aggravation in elderly patients with lung cancer undergoing chemotherapy[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(8): 491-495. [16] QIU YH, ZHONG HJ, FANG MY, et al.Recentterm efficacy of gemcitabine oxaliplatin in the treatment of 31 cases of advanced gastrointestinal tumors[J]. Journal of Oncology(肿瘤学杂志), 2004, 9(3): 175-176. |